74.11
0.47 (0.64%)
| Penutupan Terdahulu | 73.64 |
| Jumlah Dagangan | 4,758,318 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.36 |
| Harga / Jualan (P/S) | 3.30 |
| Harga / Buku (P/B) | 1.64 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 0.49% |
| Margin Keuntungan | 11.28% |
| Margin Operasi (TTM) | 13.30% |
| EPS Cair (TTM) | 2.25 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 0.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 41.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.63% |
| Nisbah Semasa (MRQ) | 2.70 |
| Aliran Tunai Operasi (OCF TTM) | 2.12 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.18 B |
| Pulangan Atas Aset (ROA TTM) | 2.74% |
| Pulangan Atas Ekuiti (ROE TTM) | 5.23% |
Sentimen Berita
-
Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition
6 hari lalu, 10:16AM
-
What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?
6 hari lalu, 2:17AM
-
Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
10 Nov, 3:30PM
-
Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript
11 Nov, 4:02PM
-
Alcon Stocks Fall 4% After Lens Implant Sales Slip and Guidance Narrows
11 Nov, 1:04PM
-
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
11 Nov, 10:37AM
AISkor Stockmoo
| Nilai 30% | 2.2 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Harga rendah berbanding pertumbuhan perolehannya. info | |
| Pertumbuhan Tersirat info | NA |
| Lebih murah daripada penilaian biasanya. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai positif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Masa 30% | 0.3 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menurun sepanjang tahun lalu. Agak di bawah paras tertinggi 52 minggu. info | |
| Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. info | |
| Corak Lilin info | NA |
| Di atas garis aliran jangka sederhana. info | |
| Sentimen 20% | 0.1 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Wang Pintar 20% | 4.9 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih +6.45% daripada saham dalam pemfailan 13F terkini: 281 pemegang menambah, 334 mengurang (suku berakhir 30 Sep 2026). info | |
| Keadaan pasaran dan sektor neutral. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor mengatasi prestasi pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga hampir dengan purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek meningkat. info | |
| Harga di antara sokongan dan rintangan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | 2.21 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Bercampur | |
| Stok | Alcon Inc. | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ALC | - | 0.49% | - | 1.64 |
| STVN | - | 0.30% | - | 2.39 |
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| BLCO | - | - | - | 1.17 |
|
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Large Growth |
| % Dimiliki oleh Orang Dalam | 0.13% |
| % Dimiliki oleh Institusi | 68.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ako Capital Llp | 30 Sep 2026 | 8,621,232 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 30 Sep 2026 | 8,013,373 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 58.20%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 281 | 45,423,731 |
| Berkurang | 334 | 29,979,026 |
| Baharu | 87 | 20,839,836 |
| Dijual habis | 88 | 5,134,527 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Are Q3 Results Altering The Investment Case For Alcon (SWX:ALC)?
Alcon reported Q3 2026 revenue of US$2.74b and net income of US$260 million, alongside a revised full year 2026 net sales growth outlook of about 6%. The business is relying more on Surgical equipment and Vision Care momentum. At the same time, U.S. premium IOL competition and slightly tighter… |
| 12 Nov 2026 | Yahoo Finance |
Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition
Alcon has delivered mixed share performance in recent years, and the question for you now is whether the current price lines up with what its cash flows can support. With fresh product approvals and an acquisition reshaping its eye care portfolio, the stock invites a closer look at what the… |
| 12 Nov 2026 | Yahoo Finance |
What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?
Alcon (SWX:ALC) reported strong Q3 2026 sales performance, underscoring momentum in its core eye care operations. The firm received US FDA approvals for new intraocular lens products intended for use in cataract and vision correction procedures. Management broadened the portfolio with the… |
| 11 Nov 2026 | Yahoo Finance |
Alcon: 3 Key Takeaways for Long-Term Investors
Alcon's defense of its premium lens franchise against competitor trials is the test that will decide whether its growth holds up. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript
Alcon narrows 2026 guidance as its Neurotech retina deal closes. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc (ALC) (Q3 2026) Earnings Call Highlights: Solid Sales Growth and Margin Expansion ...
Alcon Inc (ALC) delivered 5% sales growth and 15% core EPS growth in Q3 2026, driven by equipment and ocular health strength, while navigating implantable softness and narrowing full-year guidance. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Stocks Fall 4% After Lens Implant Sales Slip and Guidance Narrows
U.S. competition pushed implantables down 2%, and Alcon trimmed the top of its 2026 core EPS growth range. |
| 11 Nov 2026 | Yahoo Finance |
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
Alcon's Q3 earnings top estimates as sales miss, margins expand and 2026 growth targets narrow; shares slip after the report. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc. Q3 2026 Earnings Call Summary
Moby summary of Alcon Inc.'s Q3 2026 earnings call… |
| 10 Nov 2026 | Yahoo Finance |
Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
GENEVA, November 10, 2026--Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth… |
| 05 Nov 2026 | Yahoo Finance |
Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026… |
| 05 Nov 2026 | Yahoo Finance |
Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?
Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
| 04 Nov 2026 | Yahoo Finance |
Alcon Inc. (ALC) Is Positioned to Benefit From Long-Term Healthcare Demand: Here’s the Investment Case
Pershing Square Inc. recently released its Q3 2026 investor letter. A copy of the letter can be downloaded here. The letter reported 13% year-over-year growth in third-quarter fee-related earnings (FRE) to $63.7 million, while distributable earnings (DE) before taxes increased 8% to $61.0 million.… |
| Papar semua | ||
| Hasil Dividen (DY TTM) | 0.49% |
| Purata Hasil Dividen 5T | 0.20% |
| Nisbah Pembayaran | 11.81% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 14 May 2024 | 08 Apr 2024 | 16 May 2024 | 0.2644 Tunai |
| 10 May 2023 | 30 Mar 2023 | 12 May 2023 | 0.2356 Tunai |
| 29 Apr 2022 | 24 Mar 2022 | 05 May 2022 | 0.2083 Tunai |
| 04 May 2021 | 24 Mar 2021 | 06 May 2021 | 0.0909 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2024 | 0.264 | 1 | 0.31 |
| 2023 | 0.236 | 1 | 0.30 |
| 2022 | 0.208 | 1 | 0.30 |
| 2021 | 0.091 | 1 | 0.10 |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |